News

Holochem has moved to new offices

April 2019

Holochem has moved!

Holochem has relocated to larger office and brand-new laboratory space.

Please note our new address for all future shipments and correspondance :

Rue du Moulin de la Canne
45300 Pithiviers
France

PANIPAC project selected

November 2018

Photoactivable nanoparticles to immunostimulate the tumour micro-environment in pancreatic cancer

Holochem will participate in the PANIPAC project that has been selected for funding under the framework of the ERA-NET EuroNanoMed III European Innovative Research & Technological Development projects in Nanomedicine.

The PANIPAC project is coordinated by the CIBER Center for Biomedical Research Network with the objective to develop photoactivable nanoparticles to immunostimulate the tumor micro-environment in pancreatic cancer.

There is a pressing medical need to develop innovative therapeutic approaches to improve the outcome and survival of pancreatic ductal adenocarcinoma (PDAC) patients. To meet this aim, PANIPAC proposes the development of photoactivable nanoemulsions made of bioactive sphingolipids, which via a dual mechanism of action should increase the immunogenicity of pancreatic tumours. This goal can be achieved by i) reverting the tolerogenic/ immunosuppressive tumour microenvironment of pancreatic cancer by modulating the phenotype of tumor-associated immune cells, and ii) mediating the infiltration of T effector lymphocytes to reset the immunogenicity of pancreatic tumours, and make them candidates for the development of combinatory therapies with checkpoint inhibitors and/or other immune therapies such as bispecific antibodies. If successful, the project would have an enormous socio-economic impact worldwide.

Read more

METASTARG project selected

November 2018

Targeted multifunctional nanoemulsions to interrupt metastasis progression

Holochem will participate in the METASTARG project that has been selected for funding under the framework of the ERA-NET EuroNanoMed III European Innovative Research & Technological Development projects in Nanomedicine.

The METASTARG project is coordinated by the ONCOMET Translational medical Oncology Group with the objective to develop nanoparticles loaded with adenosine to protect this molecule from rapid degradation and thus interrupt metastasis progression.

The project addresses an important, so far unmet medical need. METASTARG is an innovative solution relying on nanotechnology for the early detection and treatment of OM to cause a direct impact in patient survival, quality of life, and health- economics. METASTARG Nanoemulsions are developed to identify OM by novel characteristic targets found in metastatic cells and Interrupt Metastasis Progression (NIMPs). This unique patient-driven approach has the potential to become a gold standard in the treatment and monitoring of NSCLC cancer.

Read more

Holochem is seeking an Analytical Development Team Leader

November 2017
Holochem is seeking an Analytical Development Team Leader who will be responsible for building and leading a team in the development and evaluation of analytical methods, to support pharma development and manufacture of small batches.

Read more

Holochem at CPhI Worldwide, Frankfurt, 24-26 October 2017

October 2017

Holochem at CPHI Worldwide hall 41D50 hall 4.1 ICSEHolochem was present at CPhI Worldwide, held in Frankfurt, Germany, from October 24th to 26th 2017.

We were located on the PolePharma pavilion on the ICSE International Contract Services Expo, hall 4.1, stand # 41D50.

CPhI newcomer Holochem, a brand-new CRO offering fine chemical R&D services for the development of key intermediates and exclusive APIs

October 2017

The fine chemical industry counts a new player with a highly experienced R&D and executive management team. Holochem, CPhI newcomer founded by former Sanofi executive and Holis Technologies CEO Serge Calet, is a customer-oriented Contract Research Organization.

The company offers R&D services for the development of key intermediates and Active Pharmaceutical Ingredients, and produces pre-clinical batched for early-phase formulation and toxicological use.

Read more

Holochem and Holodiag sign strategic partnership to offer integrated CMC services

September 2017
Holochem CEO Serge Calet and Holodiag CEO Pierric Marchand shaking handsHolochem, provider of Chemical and Process development services, and Holodiag, provider of Solid State solutions, announce the signing of a strategic partnership, enabling both companies to supply their customers with a full range of integrated fine chemical and API Contract Development & Manufacturing services, through all stages of the drug development lifecycle.

Read more

Holochem is seeking Chemistry lab technicians

June 2017
Holochem is seeking Chemistry lab technicians who generally work alongside chemists and other technicians. Typical job duties include organizing the lab workspace, maintaining cleanliness of equipment, creating chemical solutions, and performing chemical experiments.

Read more

Holochem is seeking a Process Chemistry Team Leader

June 2017
Holochem is seeking a Process Chemistry Team Leader to develop our laboratory manufacturing to a 20L scale. The role involves responsibilities across various stages of Chemical Development, from route selection, risk assessment and custom manufacturing up to the kilo-scale.

Read more

NanoHeart project selected

February 2017
EuroNanoMed presents the 10 projects that are selected for funding under the framework of the ENM II call. Among the selected projects is the NanoHeart project, coordinated by medical nanotechnology expert Patrick Couvreur of the Paris-Sud University, and co-developed by Holochem.

The NanoHeart project will develop nanoparticles loaded with adenosine to protect this molecule from rapid degradation.

Read more